US Stem Cell Inc (USRM)

[Dragon Lady]

10-Q released late on a Friday after market close. Must be worried the huge dilution and lack of cash, continued large operational losses and all the rest won't look too good, IMO.

Watch for a PR next week IMO, something trying to hype the "revenue" angle or something to that effect. That seems to be the norm IMO. PR to "goose" the stock, then selling into any strength. Look at the 3 month chart and match it up with PR releases.

Noticed they left the "first ever combination stem cell treatment IN THE WORLD" in the 10-Q (Page 28)("This was the first patient treated in the world using a combination of stem cells.
"). Notice, no wordsmithing, no legal word splitting about "at Magnum" or "In Honduras"- the "claim" is first IN THE WORLD, EVER. Too bad a simple PUBMED or similar search proves it's simply not true IMO. There's a "combination stem cell treatment" of a patient over 20 yrs ago, well documented on PUBMED. And numerous others, including a very formal trial that included 75 patients treated.

You'd think a "medical R&D" company would know how to do a basic PUBMED or med journal search on prior research? Maybe? That statement of the "WORLD'S FIRST" just simply isn't true, not by any stretch IMO. Too easy to find numerous examples, well published in credible journals and academia to blow that claim right out of the water.

Just a few PUBMED files to show there is a lot of prior research and work involving "combination stem cell treatment" of a patient/human, well before July of 2014, via Bioheart. How they "think" they can make that claim is pretty amazing IMO.

http://www.ncbi.nlm.nih.gov/pubmed/20398245

http://www.bloodjournal.org/content/80/7/1666?variant=short&sso-checked=1

http://www.ncbi.nlm.nih.gov/pubmed/23224061

http://www.ncbi.nlm.nih.gov/pubmed/21241969

And this one - the slam dunk, home run, not debatable IMO, as the published body-txt makes it 100% clear that the researchers not only "published prior" reports on treating a patient using a "combination of two different stem cell types", but then they went on to explore it further and did it again, in the current published report, and it's written up in great detail:

http://www.intarchmed.com/content/3/1/5

"We have previously published data from an end-stage patient suffering from dilated cardiomyopathy which underwent a profound improvement in ejection fraction after receiving a combination of cord blood expanded CD34 cells and placental matrix derived mesenchymal stem cells [136]. In the current case report we describe a patient with ischemia cardiomyopathy who received a combination of allogeneic CD34 cells and endometrial regenerative cells (ERC)"

Yeah, the FIRST IN THE WORLD? NOT. Not even close IMO. It's just too easy to prove otherwise, and what's amazing, is several of those PRIOR "combination stem cell treatments" to human patients were involving cardiac/heart research, the supposed area of "expertise" of Bioheart? How can that not be aware of prior research in their own field? How?